Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084115 | 0.89 | CNR2 (0.39) | CNR1CNR2PDE2AS100A4TACR1 | |
| SCHEMBL1754134 | 0.84 | CNR1 (0.43) | CNR1CNR2PDE2ATACR1TACR3 | |
| SCHEMBL2085215 | 0.84 | GPR119 (0.42) | PDE2ATACR1TACR3 | |
| SCHEMBL4121650 | 0.79 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL4114197 | 0.78 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL1754000 | 0.77 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL2087359 | 0.76 | MAP4K4 (0.42) | — | |
| SCHEMBL1754118 | 0.75 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL4120384 | 0.75 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL2055577 | 0.75 | NR3C1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | CNR1 285/4885CNR2 1046/4885PDE2A 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.